Illumina
Update in progressILMN (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
Illumina provides sequencing- and array-based solutions for genetic and genomic analysis worldwide. It offers instruments, consumables, and kits for whole-genome and targeted resequencing (exomes, genes, RNA), as well as genotyping and noninvasive prenatal testing, plus product support services. Customers include research centers, universities, government labs, hospitals, pharma/biotech/diagnostic labs, and consumer genomics firms. Sells directly and via distributors, and partners with Labcorp on oncology sequencing. Founded 1998 in San Diego.
Company score
- Sentiment
- 1.61
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.65
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 1.96
- Governance
- 0.41
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.89
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 1.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!